Home / Stocks / Pfizer Ltd
PFIZER

Pfizer Ltd Share Price

Live price, chart and which mutual funds hold this stock

…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 19 Nov 2026

₹3,850.3

Change

+8.5 (0.22%)

Open

₹3,838.0

Prev. Close

₹3,841.8

Day High

₹3,859.9

Day Low

₹3,801.2

Volume Analysis

Traded

12,312

Delivered

6,816

Delivery %

55.36%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (0)

No signal for this stock

Weaknesses (1)

  • •Low operating margin (-12.0%)

Opportunities (0)

No signal for this stock

Threats (1)

  • •FII holding has been falling

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹3,931.76 ₹3,895.83 ₹3,873.06 ₹3,837.13 ₹3,814.36 ₹3,778.43 ₹3,755.66
Fibonacci ₹3,895.83 ₹3,873.41 ₹3,859.55 ₹3,837.13 ₹3,814.71 ₹3,800.85 ₹3,778.43
Camarilla ₹3,866.44 ₹3,861.06 ₹3,855.68 ₹3,837.13 ₹3,844.92 ₹3,839.54 ₹3,834.16

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

-21.68%

1 Week

-0.36%

1 Month

+2.55%

3 Months

-22.66%

6 Months

-17.57%

1 Year

-23.43%

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

Graham Number

₹825.92

Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.

DuPont ROE Breakdown

33.47%

Net margin 44.25% × asset turnover 0.62x × equity multiplier 1.22x

Company Overview

Sector

Healthcare

Market Cap

₹17,601 Cr

P/E (TTM)

115.0

ROE

19.8%

Book Value

₹302.0

Face Value

₹10.0

Source: Screener.in (Consolidated figures) — data as of 19 Nov 2026. Not investment advice.

TopFund Analysis

Pfizer Ltd lands in the middle of the pack on TopFund's composite fundamentals check within the Healthcare sector, at 58/100. The strongest factor is Financial Strength (100/100), while Valuation (8/100) is the weakest area to weigh before deciding. Notably: Low operating margin (-12.0%). FII holding has been falling.

TopFund Score — Fundamentals Quality

58/100 — Average

Data confidence: 76/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.

As of 19 Nov 2026 · How we calculate this →

Financial Strength

100

Valuation

8

Cash Flow

72

Corporate Governance

76

Momentum

15

Institutional Ownership

43

Business Quality

75

Risk & Volatility

61

Liquidity

34

From Screener.in

  • +Company is almost debt free.
  • +Company has been maintaining a healthy dividend payout of 33.2%
  • −Stock is trading at 12.7 times its book value
  • −Earnings include an other income of Rs.512 Cr.
  • −Working capital days have increased from 60.8 days to 135 days

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Pfizer submitted Regulation 74(5) compliance certificate for quarter ended September 30, 2026.

Copy of newspaper advertisements for Transfer and Dematerialisation of Physical Securities.

Trading window closed from September 30, 2026 until 48 hours after half-year results.

Source: BSE regulatory filings, via Screener.in.

Profit & Loss (Yearly)

  Nov 2006 Nov 2007 Nov 2008
Sales + 664 676 678
Expenses + 537 815 760
Operating Profit 127 -139 -82
OPM % 19.0% -21.0% -12.0%
Other Income + 48 600 512
Interest 0 0 0
Depreciation 13 10 11
Profit before tax 163 451 419
Tax % 35.0% 25.0% 29.0%
Net Profit + 106 340 300
EPS in Rs 36 114 100
Dividend Payout % 63.0% 24.0% 12.0%
Sales growth — 2 0

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Nov 2006 Nov 2007 Nov 2008
Reserves 376 620 871
Borrowings + 0 0 0
Other Liabilities + 240 218 197
Total Liabilities 646 867 1,098
Fixed Assets + 65 60 51
CWIP 2 10 32
Investments 0 0 0
Other Assets + 579 797 1,014
Total Assets 646 867 1,098
Equity Capital 30 30 30

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Nov 2006 Nov 2007 Nov 2008
Cash from Operating Activity + 123 17 238
Cash from Investing Activity + 7 232 -79
Cash from Financing Activity + -34 -76 -95
Net Cash Flow 97 173 64
Free Cash Flow 120 283 213
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 148 -93 -446

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 63.92% → 63.92%
  Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Public 17.87% 17.42% 17.0% 16.5% 16.54% 16.79% 16.45% 16.37% 16.32% 16.36% 16.62% 16.93%
Promoters 63.92% 63.92% 63.92% 63.92% 63.92% 63.92% 63.92% 63.92% 63.92% 63.92% 63.92% 63.92%
FII 3.03% 3.32% 3.22% 3.54% 2.74% 2.18% 2.4% 2.6% 2.71% 2.81% 1.65% 1.63%
DII 15.15% 15.32% 15.83% 16.03% 16.8% 17.1% 17.23% 17.11% 17.05% 16.89% 17.8% 17.52%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Pfizer Ltd (this stock) 17,601 115.0 12.74 19.8%
Cohance Lifesciences Ltd 17,511 359.0 4.49 4.89%
Dr Agarwals Health Care L 17,460 97.5 7.8 6.41%
Alivus Life Sciences Ltd 17,803 50.6 — —
Caplin Point Lab Ltd. 17,863 25.9 4.58 20.9%
Syngene International Ltd 17,935 67.5 3.7 7.78%
Molbio Diagnostics Ltd 17,111 236.0 11.89 15.6%

Which Mutual Funds Hold Pfizer Ltd?

Frequently Asked Questions about Pfizer Ltd

Community Sentiment

What are other investors saying about Pfizer Ltd?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.